85 results about "A baumannii" patented technology

The invention belongs to the technical field of antibacterial peptides, and particularly relates to an antibacterial peptide Mh-GC21 as well as a precursor and application thereof. The amino acid sequence of the antibacterial peptide Mh-GC21 provided by the invention is as shown in SEQ ID NO.1, and two cysteines are oxidized to form a pair of intermolecular disulfide bonds; the C tail end of the antibacterial peptide Mh-GC21 is subjected to amidation modification. The antibacterial peptide Mh-GC21 provided by the invention is from microhyla microcarpa, has broad-spectrum antibacterial activity, has relatively good antibacterial and bactericidal effects on standard strains of acinetobacter baumannii, escherichia coli and staphylococcus aureus and clinically sourced drug-resistant strains, and can be used for targeted destruction of cell membranes of bacteria, removal of biological membranes and inhibition of formation of the biological membranes. Moreover, the antibacterial peptide Mh-GC21 has the advantages of good stability, no hemolytic activity and cytotoxicity, and difficulty in inducing strains to generate drug resistance.

The invention discloses acinetobacter baumannii and application of the acinetobacter baumannii in construction of a mastitis animal model. The acinetobacter baumannii strain is acinetobacter baumannii AbST3475NMG202308, and the preservation number of the acinetobacter baumannii strain is CGMCC (China General Microbiological Culture Collection Center) No.34450 in the General Microbiological Culture Collection Center of the China Committee for Culture Collection of Microorganisms). Experiments prove that the acinetobacter baumannii has high pathogenicity and can be used for establishing a typical animal model caused by acinetobacter baumannii infection, the animal model can be specifically a mastitis animal model, and a certain technical support is provided for subsequent research and development of drugs or vaccines; the acinetobacter baumannii can also be used for screening antibacterial drugs and developing diagnostic reagents and vaccines. The method has an important application value.

The invention provides a fluorenyl alcohol derivative which can be used as an antibiotic adjuvant with a broad-spectrum synergistic effect. According to the compound, bacteria outer membrane asymmetric protein MlaC and phospholipase A1 PldA are taken as targets, and a series of fluorenyl alcohol derivatives targeting the bacteria outer membrane asymmetric protein MlaC and phospholipase A1 PldA are obtained through screening. The preferable compound WTU-15 can improve the antibacterial activity of antibiotics such as polymyxin, cefepime, tetracycline and the like on negative bacteria such as sensitive and drug-resistant escherichia coli, salmonella, klebsiella pneumoniae, acinetobacter baumannii and the like, and can also improve the in-vivo treatment effect of cefepime on mice infected by the drug-resistant acinetobacter baumannii. And the visceral organs of the mice survived after administration have fewer bacteria, and the mice are better after being healed. Normal physiological and visceral organ functions of the mouse are not affected by single and continuous administration of the WTU-15.

The present invention relates to the technical field of phages. Provided are a KL2-type Acinetobacter baumannii phage and a screening method therefor, a phage composition and the use, and a drug. The KL2-type Acinetobacter baumannii phage is named AB_SZL2, and is deposited in the China Center for Type Culture Collection with the deposit number CCTCC NO: M20241522; or the KL2-type Acinetobacter baumannii phage is named AB_SZL3, and is deposited in the China Center for Type Culture Collection with the deposit number CCTCC NO: M20241523. The KL2-type Acinetobacter baumannii phage can accurately target KL2-type Acinetobacter baumannii, and has an efficient bactericidal effect, thereby reducing the harm of KL2-type Acinetobacter baumannii and effectively addressing the problem of the antibiotic resistance of KL2-type Acinetobacter baumannii.

The invention belongs to the technical field of bacterium detection, and discloses a multiple PCR primer for simultaneously detecting eight respiratory tract pathogenic bacteria and application thereof. On the basis of a Luminex liquid phase chip technology, specific primers are designed aiming at eight common respiratory tract infection pathogenic bacteria including pseudomonas aeruginosa, staphylococcus aureus, streptococcus pneumoniae, klebsiella pneumoniae, acinetobacter baumannii, stenotrophomonas maltophilia, haemophilus influenzae and escherichia coli; the multiple PCR primers which are high in amplification efficiency, good in specificity and suitable for simultaneously detecting the eight respiratory tract pathogenic bacteria are screened out, the multiple PCR system and microsphere hybridization conditions are continuously optimized, the multiple PCR method for the eight respiratory tract pathogenic bacteria is successfully constructed by applying the Luminex xTAG technology, and the multiple PCR method can be applied to rapid detection of multiple pathogenic microorganisms.

The invention discloses application of a cyclic peptide compound BIM 23042 or a preparation thereof in preparation of medicines for treating bacterial infectious diseases, and belongs to the technical field of medicines. The invention discloses a cyclic peptide compound BIM 23042 as an antibiotic synergist for the first time, and the cyclic peptide compound BIM 23042 is used for treating bacterial infectious diseases. According to the application disclosed by the invention, the cyclopeptide compound BIM 23042 and polymyxin are combined for use, so that the growth of gram-negative bacteria can be effectively and synergistically inhibited. The combined medication scheme shows a remarkable advantage in coping with acinetobacter baumannii. The cyclic peptide compound BIM 23042 disclosed by the invention has an anti-infection capability, and the anti-infection capability is specifically shown as reducing the inflammatory response of macrophage RAW 264.7 induced by LPS (Lipopolysaccharide) and also reducing the apoptosis of the macrophage RAW 264.7 caused by the LPS. The invention provides a new perspective for developing a novel drug-resistant gram-negative bacterium prevention and control strategy, and also provides a new treatment scheme for coping with bacterial infection.

The invention belongs to the technical field of strain identification and drug sensitivity detection, and discloses a strain identification and drug sensitivity detection kit and a preparation method and application thereof, the kit comprises a drug sensitivity disc, a pre-enrichment chromogenic culture medium, a chromogenic culture medium, sterile water and a diluent; the drug sensitive disc body comprises an enterobacteriaceae area, an enterococcus area, a staphylococcus area, a pseudomonas aeruginosa area and an acinetobacter baumannii area; the enterobacteriaceae area is provided with enterobacteriaceae identification culture medium micropores and drug micropores, the enterococcus area is provided with enterococcus identification culture medium micropores and drug micropores, the staphylococcus area is provided with staphylococcus identification culture medium micropores and drug micropores, and the pseudomonas aeruginosa area is provided with pseudomonas aeruginosa identification culture medium micropores and drug micropores. An acinetobacter baumannii identification culture medium micropore and a medicine micropore are matched in the acinetobacter baumannii area; the problems that an existing drug sensitivity test mode is complex in operation, high in cost and low in accuracy of identification and detection results are solved.

The invention discloses a novel acinetobacter baumannii phage vBAbaMpha0264 and application thereof, and belongs to the technical field of microorganisms. The acinetobacter baumannii phage vBAbaMpha0264 is preserved in the Guangdong Microbiological Culture Collection Center on August 28, 2025, the preservation number of the acinetobacter baumannii phage vBAbaMpha0264 is GDMCC (China General Microbiological Culture Collection Center) NO: 66893-B1, and the preservation address of the acinetobacter baumannii phage vBAbaMpha0264 is Institute of Microbiology, Academy of Sciences, Guangdong. The bacteriophage vBAbaMpha0264 has high cracking activity, environmental stability and safety, shows a breakthrough host range, and can be used for effectively cracking a plurality of acinetobacter bacteria including hospital acinetobacter and acinetobacter sysei. Meanwhile, the bacteriophage has excellent chloroform tolerance, and the stability of the bacteriophage is obviously superior to that of the existing bacteriophage. Due to the characteristics, the phage vBAbaMpha0264 overcomes the technical prejudice of'narrow spectrum and instability 'of the traditional phage, and a brand new technical scheme is provided for developing a universal antibacterial preparation covering more pathogenic bacteria.

The invention belongs to the technical field of medicines, and particularly relates to an aryl dicarboxylic acid compound, a preparation method and application of the aryl dicarboxylic acid compound as an antibacterial agent. The compound is shown as a formula (1), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are independently selected from hydrogen and halogen. Two ends of the molecule are connected through an N-phenylpropanamide connecting arm, the molecule is a compound with a novel structure, and the series of compounds have a relatively strong inhibition effect on acinetobacter baumannii and are worthy of further research and development.

The application belongs to the technical field of antibacterial peptides, and particularly relates to an antibacterial peptide Mp-GC21, a precursor thereof and application. The amino acid sequence of the antibacterial peptide Mp-GC21 is shown as SEQ ID NO:1, wherein the C terminal is subjected to amidation modification, and two cysteines are connected through a disulfide bond; and the amino acid sequence of the precursor is shown as SEQ ID NO:3. The antibacterial peptide Mp-GC21 is separated from the flower frog, has broad-spectrum antibacterial activity, and has good bacteriostatic and bactericidal effects on standard strains and clinically derived drug-resistant strains of Acinetobacter baumannii, Escherichia coli and Staphylococcus aureus, and can target to destroy the cell membrane of bacteria, remove the biofilm and inhibit the formation of the biofilm. Moreover, the antibacterial peptide Mp-GC21 has good stability, does not have hemolytic activity, cytotoxicity and in-vivo toxicity, and is not easy to induce drug resistance of strains.

A polyclonal antibody composition specifically binds the pTonB epitope (SEQ ID NO: 11) from Acinetobacter baumannii and is elicited by immunization with a multi-epitope antigen comprising thioredoxin leader, rigid linker, and kernels including SEQ ID NOs: 6, 7, 11, 12, and 8. These antibodies enhance opsonophagocytic killing of A. baumannii Ci79 via classical complement activation and Fey receptor-mediated phagocytosis by bone marrow-derived macrophages. Absorption of pTonB-specific antibodies reduces killing by >70%, confirming epitope dominance. Passive transfer of the composition protects >60% of mice in a lethal intranasal challenge model. Pharmaceutical compositions, treatment methods (alone or with antibiotics like colistin), prophylactic uses, diagnostic kits, and polyclonal compositions are disclosed for combating multidrug-resistant A. baumannii infections.

The invention relates to the technical field of bacteriophages, and particularly discloses an acinetobacter baumannii bacteriophage, depolymerases and a preparation method and application of the acinetobacter baumannii bacteriophage. The acinetobacter baumannii bacteriophage P919 provided by the invention has very strong specific lysis capability on KL3 type acinetobacter baumannii, and the coded depolymerases of the acinetobacter baumannii bacteriophage P919 have excellent temperature stability at 70 DEG C or below, and can effectively degrade capsular polysaccharide of the KL3 type acinetobacter baumannii.

The invention discloses an antibody as well as a preparation method and application thereof. The antibody has good binding activity with OXA-23 type carbapenem enzyme, and can reduce the carbapenem drug resistance level of the acinetobacter baumannii, so that the clinical use concentration of meropenem is reduced, and the treatment effect of meropenem on the acinetobacter baumannii is improved. In addition, the antibody disclosed by the invention can also inhibit OXA-23 protein secreted by bacteria, prevent the bacteria from hydrolyzing carbapenem antibiotics, increase the concentration of antibiotics in a medication part, and facilitate the removal of mixed infection with acinetobacter baumannii. The invention provides a new strategy for treating acinetobacter baumannii infection, and the application prospect is wide.

The application belongs to the technical field of medicine, and particularly relates to a cyclic peptide compound and application thereof in the field of antibiosis. The application discloses a cyclic peptide compound, the structure of which is shown as formula I. The preliminary experiment verifies that the compound has good effects of resisting Acinetobacter baumannii, and has wide application prospects.

The invention belongs to the technical field of antibacterial peptides, and particularly relates to an antibacterial peptide Z34B3 and application thereof. The amino acid sequence of the antibacterial peptide Z34B3 provided by the invention is shown as SEQ ID NO: 1, the secondary structure is an alpha helix, the molecular weight is small, and the antibacterial peptide Z34B3 can change the cell membrane permeability of various gram-negative bacteria including pasteurella multocida, escherichia coli and acinetobacter baumannii, inhibit the generation of cell membranes and play antibacterial and bactericidal roles. Moreover, the antibacterial peptide Z34B3 provided by the invention has low hemolytic activity and no cytotoxicity, and can be applied to preparation of products with bacteriostatic and bactericidal effects and preparation of drugs for preventing and / or treating bacterial infectious diseases. Furthermore, the C tail end of the antibacterial peptide Z34B3 is subjected to amidation modification, and compared with non-modification treatment, the stability can be improved.

The invention discloses recombinant bacteriophage lyase and application thereof. The amino acid sequence of the recombinant bacteriophage lyase E8-3 is as shown in SEQ ID NO: 43, and an in-vitro minimum inhibitory concentration experiment shows that the recombinant bacteriophage lyase E8-3 has a bacteriostatic effect on helicobacter pylori and acinetobacter baumannii, and particularly has a wide application prospect in the development of anti-helicobacter pylori drugs.

The invention discloses an establishment and application method of an acute pneumonia animal model for an acinetobacter baumannii vaccine immune effect test, and the method comprises the following steps: S1, screening experimental animals, and feeding; s2, experiment grouping and identification; s3, constructing an animal model; and S4, performing data statistical analysis. According to the animal model, common clinical infection pathways, infection parts, pathogenesis, pathological changes and clinical manifestations of the acinetobacter baumannii can be simulated to the maximum extent, and the pertinence and accuracy of candidate vaccine curative effect judgment and prediction are improved.

The invention belongs to the field of biological pharmacy, and particularly relates to a chalcanthicidin compound and application thereof. The invention discloses a chalcanthicidin compound which is separated from a secondary metabolite of marine actinomycetes Streptomyces sp. KCB-132 (marine actinomycetes sp. KCB-132). Pharmacological activity experiments show that the compound has a moderate inhibition effect on ESKAPE pathogenic bacteria with multiple drug resistance, such as enterococcus faecium, staphylococcus aureus, klebsiella pneumoniae, acinetobacter baumannii and escherichia coli. Therefore, the compound has the potential of being developed into a novel antibacterial agent.

The present application relates to the fusion protein, immunogenic composition, recombinant vaccine and application for preventing acinetobacter baumannii infection, etc. The present application screens and obtains four groups of antigen combination fusion protein mRNA vaccines of AdeK-LolB, Omp22-HphA, Omp22-LolB and CsuE-CsuAB, which show excellent effects in the mouse acinetobacter baumannii infection model. Compared with the nucleic acid vaccine encoded by the Omp22-Omp38 fusion protein known in the prior art and having excellent effects itself, the nucleic acid vaccine has better immunization effects and protective effects for preventing acinetobacter baumannii infection in reducing acinetobacter baumannii colonization and reducing the degree of lesions caused by infection, and has a wide application prospect.

The invention discloses application of chlorpromazine hydrochloride in preparation of an acinetobacter baumannii infection resisting medicine, and belongs to the technical field of biological medicine. The invention proves that when the chlorpromazine hydrochloride is independently used, the growth of the acinetobacter baumannii can be inhibited, wherein the acinetobacter baumannii comprises colistin-resistant acinetobacter baumannii; meanwhile, chlorpromazine hydrochloride can cooperate with colistin to play a role in resisting acinetobacter baumannii, so that infection caused by colistin-resistant acinetobacter baumannii is treated. When a certain concentration of chlorpromazine hydrochloride and colistin are combined for use, more than 50% of colistin-resistant acinetobacter baumannii is killed within 4 hours, and the survival rate is lower than 1%, which proves that chlorpromazine hydrochloride and colistin have a synergistic effect. The chlorpromazine hydrochloride and the colistin are combined for use, so that the chlorpromazine hydrochloride and the colistin can be used for resisting colistin drug-resistant pathogens and treating diseases caused by colistin drug-resistant bacteria infection, and meanwhile, the evolution of colistin drug resistance can also be prevented.

This invention relates to the fields of environmental microbiology and wastewater treatment technology, specifically to a highly salt-tolerant Acinetobacter baumannii strain for heterotrophic nitrification and aerobic denitrification of wastewater, a microbial agent, and its application. The strain is Acinetobacter baumannii. Acinetobacter baumannii M4, deposited on May 12, 2025, at the Guangdong Provincial Microbial Culture Collection Center, located at 5th Floor, Building 59, No. 100 Xianlie Middle Road, Yuexiu District, Guangzhou, Guangdong Province, with accession number GDMCC No: 66302. This invention utilizes the *Acinetobacter baumannii* strain M4, domesticated using a multi-round salt-beating method. It can grow in high-salt-alkali environments and exhibits both heterotrophic nitrification and aerobic denitrification capabilities. It can be widely applied to the biological denitrification and phosphorus removal treatment of high-salt-alkali nitrogen and phosphorus wastewater, including wastewater from aquaculture, pickling, and industrial processes.

The invention discloses a protein fermentation, purification and preparation process of acinetobacter baumannii vaccine antigen Ata fragment protein. The process comprises the following steps: S1, carrying out inoculated culture through a shake flask; s2, thalli are collected; s3, crushing the thalli, and carrying out centrifugal clarification; s4, anion chromatography; s5, hydrophobic chromatography; s6, desalting and changing liquid; and S7, obtaining the high-purity Ata fragment protein. According to the method, a process from small-scale strain fermentation to separation and purification is established, a protein sample with the yield of-g level is finally obtained by combining anion exchange, hydrophobic chromatography, ultrafiltration and other methods, and the protein purity reaches 99%.

The application discloses a liposome vaccine of Acinetobacter baumannii outer membrane protein and a preparation method and application thereof, and relates to the field of biological medicines. The application efficiently expresses the Acinetobacter baumannii outer membrane protein through a genetic engineering method, and obtains a liposome vaccine of Acinetobacter baumannii outer membrane protein by combining the obtained various outer membrane proteins as antigens with a lipid mixture and an adjuvant. It is verified that the vaccine can provide complete protection for mice attacked by a lethal dose of Acinetobacter baumannii. In the application, the outer membrane protein loaded in the liposome is re-folded in structure, the immunogenicity of the protein is enhanced, and the liposome can reduce the toxicity of the outer membrane protein. Omp38+BauA+FimA can be an effective antigen combination for preventing Acinetobacter baumannii infection. Pam2CSK4 as a TLR2 agonist has a strong auxiliary effect on the liposome vaccine of Acinetobacter baumannii, and can induce the activation of an innate immune response, thereby providing more comprehensive protection for a host.

This invention relates to the field of high-throughput targeted sequencing technology, and particularly to a primer set and its applications for detecting important drug resistance and virulence genes in multidrug-resistant pathogens. Specifically, it includes primers for detecting various drug-resistant bacteria, such as third-generation cephalosporin-resistant Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, carbapenem-resistant Acinetobacter baumannii, and rifampicin-resistant Mycobacterium tuberculosis. This invention offers advantages such as speed, efficiency, strong targeting, and high specificity. It is suitable for analyzing the prevalence and differential distribution of multiple important drug resistance and virulence genes carried in metagenomic samples from various environments or pathogenic materials, and can be used to assess the risk of related environments, further guiding preventative and clinical treatment medications.

The application relates to the technical field of biological medicine, and particularly discloses application of indole-3-methanol in preparation of polymyxin antibacterial synergist and a gram-negative bacterium-resistant pharmaceutical composition, the application of the indole-3-methanol in preparation of the polymyxin antibacterial synergist, the concentration of the polymyxin and the indole-3-methanol is 0.01-2 (mu g / mL):0.01-10 mM; the gram-negative bacterium-resistant pharmaceutical composition comprises the polymyxin and the indole-3-methanol, and further comprises pharmaceutically acceptable adjuvants and / or carriers; the composition can be prepared into injections, ointments or aerosols, and can be used for treating klebsiella pneumoniae, bauman acinetobacter, escherichia coli or pseudomonas aeruginosa and the like; the application discloses that the indole-3-methanol can synergize with the polymyxin, significantly improves the bactericidal activity of the polymyxin on gram-negative bacteria, reduces the use dosage of the polymyxin, improves the antibacterial efficacy, prolongs the antibacterial time, and delays the generation of drug resistance.

The invention discloses an external antibacterial medicine composition as well as a preparation method and application thereof, and belongs to the technical field of antibacterial medicines. The external antibacterial pharmaceutical composition provided by the invention comprises a medicinal active component and a pharmaceutically acceptable carrier, wherein the medicinal active component comprises polymyxin B sulfate, trimethoprim sulfate and lidocaine; every 10 g of the antibacterial pharmaceutical composition for external use is prepared from the following components in parts by weight: 40000 to 60000 U of polymyxin B sulfate, 0.08 to 0.16 g of trimethoprim sulfate and 0.30 to 0.35 g of lidocaine. The pharmaceutical composition disclosed by the invention has broad-spectrum inhibition on multiple drug-resistant bacteria such as common gram-negative drug-resistant bacteria and acinetobacter baumannii on a wound surface, synchronously plays a synergistic role in relieving inflammatory response of the wound surface and relieving local pain, and remarkably improves the medication safety and the comprehensive treatment effect while ensuring excellent antibacterial activity.

The invention discloses an antibacterial 10 peptide, which is characterized in that the sequence of the antibacterial 10 peptide is w-k-r-w-r-r-r-w-w-r-r (dTrp-dLys-dArg-dTrp-dArg-dArg-dTrp-dTrp-dArg-dArg), and all amino acids are D-type amino acids. The antibacterial peptide provided by the invention has good antibacterial activity on various pathogenic bacteria, can be synthesized through an Fmoc solid-phase chemical method, and is low in synthesis difficulty and relatively good in-vivo antibacterial activity. The antibacterial peptide has broad-spectrum killing activity on multidrug-resistant acinetobacter baumannii, carbapenem-resistant pseudomonas aeruginosa and standard strains of acinetobacter baumannii, pseudomonas aeruginosa, klebsiella pneumoniae, escherichia coli, enterobacter cloacae, methicillin-resistant staphylococcus aureus and staphylococcus aureus, and is low in hemolytic toxicity and high in killing activity. Under medium and low concentration (2 microgram / mL to 32 microgram / mL), the cell survival rate can reach more than half, and the cell culture medium has no toxic effect on cells, and is good in stability, strong in operability and low in cost.

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus johnsonii with a function of resisting multiple drug-resistant bacterium biological membranes and anti-inflammatory activity and application of the lactobacillus johnsonii. The lactobacillus johnsonii A25041 provided by the invention has strong inhibition and anti-biofilm activity on multi-drug-resistant gram-negative bacteria (including escherichia coli, pseudomonas aeruginosa and acinetobacter baumannii) and methicillin-resistant staphylococcus aureus, and the lactobacillus johnsonii A25041 has good acid-base tolerance and gastrointestinal fluid tolerance, so that the lactobacillus johnsonii A25041 can be used for preparing medicines for preventing and treating various diseases. The composition shows excellent anti-inflammatory activity and oxidation resistance, does not have hemolysis capacity, is good in safety, has natural drug resistance to gentamicin, tetracycline, ciprofloxacin, lincomycin and compound sulfamethoxazole, can be used together with antibiotics at the same time or in sequence, maintains intestinal microecological balance and relieves antibiotic burden while exerting the sterilization effect of the antibiotics, and has a good application prospect. The method can be widely applied to functional food development, and has important application value in the field of biological medicine and daily chemical products.

The invention belongs to the technical field of medicines, and particularly relates to a cyclic peptide compound and application thereof in the antibacterial field. The invention discloses a cyclic peptide compound of which the structure is shown as a formula I. Preliminary experiments prove that the compound has a good acinetobacter baumannii resisting effect and has a wide application prospect.

The application discloses a method for constructing an animal model of chronic pulmonary infection / persistence of Acinetobacter baumannii, and belongs to the technical field of infectious disease animal model construction and microbial preparation. Compared with the acute infection and rapid clearance mode formed by directly inoculating free bacteria, the live bacterial microspheres prepared in the application can prolong the local exposure and detectable time of Acinetobacter baumannii in the lung, so that the Acinetobacter baumannii is more likely to form a low-load, long-term persistence pulmonary infection state, thereby providing a more stable experimental platform for the mechanism of chronic infection formation, host immune dynamic change and related intervention evaluation.